183
Participants
Start Date
February 7, 2012
Primary Completion Date
January 8, 2016
Study Completion Date
January 8, 2016
Rituximab
Rituximab was administered by IV infusion as a dose of 375 mg/m\^2 on Day 2 of Cycle 1 and then at 500 mg/m\^2 on Day 1 of up to 5 subsequent 28-day cycles
Bendamustine
Bendamustine was administered by IV infusion as a dose of 70 mg/m\^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
MEDI-551
MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
Research Site, Birmingham
Research Site, Burbank
Research Site, La Jolla
Research Site, Palm Springs
Research Site, Skokie
Research Site, Shreveport
Research Site, Baltimore
Research Site, Detroit
Research Site, Fargo
Research Site, Dayton
Research Site, Newark
Research Site, Watertown
Research Site, Lubbock
Research Site, Morgantown
Research Site, Antwerp
Research Site, Arlon
Research Site, Kortrijk
Research Site, Mons
Research Site, Wilrijk
Research Site, Yvoir
Research Site, Toronto
Research Site, Greenfield Park
Research Site, Montreal
Research Site, Amiens
Research Site, Bayonne
Research Site, Bordeaux
Research Site, Le Mans
Research Site, Libourne
Research Site, Marseille
Research Site, Nîmes
Research Site, Dortmund
Research Site, Essen
Research Site, Freiburg im Breisgau
Research Site, München
Research Site, Würzburg
Research Site, Haifa
Research Site, Ramat Gan
Research Site, Bari
Research Site, Lecce
Research Site, Meldola
Research Site, Milan
Research Site, Modena
Research Site, Napoli
Research Site, Orbassano
Research Site, Palermo
Research Site, Pisa
Research Site, Ravenna
Research Site, Rimini
Research Site, Roma
Research Site, San Giovanni Rotondo
Research Site, Torino
Research Site, Udine
Research Site, Gdynia
Research Site, Warsaw
Lead Sponsor
MedImmune LLC
INDUSTRY